Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Summary not available.
Veracyte (NASDAQ: VCYT) announced findings from a meta-analysis presented at ENDO 2022, reinforcing the Afirma Genomic Sequencing Classifier's (GSC) accuracy in ruling out thyroid cancer in patients with indeterminate nodules. The analysis of 13 studies indicates a sensitivity of 97% and a negative predictive value of 99%, mirroring original clinical validation. Notably, the Afirma GSC showed a 65% positive predictive value for malignancy in suspicious nodules, surpassing the initial 47% noted in earlier validations. This underscores the test's effectiveness in reducing unnecessary surgeries.
Veracyte (Nasdaq: VCYT) announced significant findings from the SAKK 09/10 trial, a phase 3 study involving 226 patients with biochemical recurrence of prostate cancer. The Decipher Prostate genomic classifier demonstrated its ability to identify patients at high risk for cancer progression post-radical prostatectomy, guiding timely and effective treatment decisions. Patients with high Decipher scores were over twice as likely to experience progression. This study supports the utility of Decipher Prostate in personalized treatment strategies, enhancing patient outcomes.
New data from Veracyte's Immunoscore Immune Checkpoint assay indicates potential for improving treatment of metastatic colorectal cancer (mCRC) by identifying patients likely to benefit from immune checkpoint inhibitors. Findings from the AtezoTRIBE trial, published in The Lancet Oncology, show a modest benefit when atezolizumab is added to standard treatment. The study reveals a significant correlation between high Immunoscore IC results and treatment response, marking it as a potential predictive tool for mCRC patients.
Veracyte announced new data from a significant study involving over 10,000 men, highlighting the clinical utility of the Decipher Prostate genomic classifier. The findings suggest that Decipher tests can effectively guide prostate cancer treatment decisions, leading to improved patient care. Results indicate that men with low-risk scores are more likely to choose active surveillance, whereas those with higher-risk scores tend to opt for radical prostatectomy. This collaboration aims to enhance data for oncology researchers through the National Cancer Institute's SEER program.
Veracyte, Inc. (Nasdaq: VCYT) announced data from a clinical study showcasing the Immunoscore Immune Checkpoint (IC) assay's ability to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). Presented at the ASCO Annual Meeting on June 6, the study involved 265 patients, revealing that 100% of those with a high-risk score relapsed within 18 months, while a significant proportion of low-risk patients did not relapse for at least 36 months. The findings aim to enhance patient selection in clinical trials and optimize treatment approaches.
Veracyte (Nasdaq: VCYT) has announced CEO Marc Stapley and CFO Rebecca Chambers will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 10:40 a.m. PT, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 2:40 p.m. PT. Live audio webcasts will be accessible on Veracyte's website, with replays available for 90 days post-event. Veracyte is a global diagnostics firm focused on improving patient care through advanced diagnostic tests that address prevalent cancers and reduce unnecessary procedures.
Veracyte, Inc. (NASDAQ: VCYT) has presented new data on its Percepta Nasal Swab test at the American Thoracic Society 2022 International Conference. The test accurately assesses lung cancer risk in current and former smokers with lung nodules, irrespective of their smoking history. The study involved 291 smokers and highlighted its 96% sensitivity and 94% specificity for identifying high-risk nodules. The data suggests potential for reducing unnecessary procedures and facilitating timely treatment for lung cancer patients. Veracyte aims to enhance clinical utility evidence for reimbursement.
Veracyte has received favorable recognition in a new clinical guideline from the American Urological Association and the American Society for Radiation Oncology for its Decipher Prostate genomic classifier. This updated guideline emphasizes the significance of genomic testing in guiding treatment for localized prostate cancer, citing comprehensive evidence from phase 3 randomized clinical trials. The Decipher Prostate test helps predict cancer outcomes and assists physicians in making informed treatment decisions, ultimately improving patient care.
Veracyte (Nasdaq: VCYT) announced the presentation of six abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. These abstracts highlight the company's genomic and immuno-oncology tests, showing their potential to enhance cancer treatment outcomes, particularly in identifying patients with non-small cell lung cancer who may benefit from immune checkpoint inhibitors. CEO Marc Stapley emphasized the importance of these findings in advancing personalized medicine.